FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes FDA Finally OKs Dapagliflozin/Saxagliptin for Type 2 Diabetes
After first rejecting it at the end of 2015, the FDA has now approved the AstraZeneca DPP-4 inhibitor/SGLT2 inhibitor fixed-dose combination product Qtern for type 2 diabetes in adults.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
More News: AstraZeneca | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | SGLT2 Inhibitors